Lipid nanoparticle-enabled gene editing in the lung via inhalation

The ability to create in vivo genomic medicines for tissues other than the liver has been impeded by difficulties in delivery. Using a high-throughput platform, we developed lipid nanoparticles that can effectively deliver mRNA and CRISPR-Cas9 gene editing tools to the lungs through intratracheal administration, expanding the potential clinical uses of gene editing and mRNA-based technologies.

Automated summary

A high-throughput platform has been developed to create lipid nanoparticles capable of delivering mRNA and CRISPR-Cas9 gene editing tools effectively to the lungs via intratracheal administration, expanding the potential clinical applications of gene editing and mRNA-based technologies.